GlaxoSmithKline Consumer Healthcare Limited announces results for the quarter 2, 2017
08 November 2017
GlaxoSmithKline Consumer Healthcare Limited announces results for the quarter ended September 30, 2017
Comparable* Revenue growth of 4.8%, PBT growth of 3.6%
Highlights for the first quarter ended September 30, 2017
- Revenue for the quarter is at Rs. 1115 crores and Profit before tax (PBT) at Rs. 298 crores
- Health food drink portfolio continues to be the market leader with 55.6% (Value share) and 63.9% (Volume share) – (MAT September 2017)
Gurugram, 07 November, 2017: GlaxoSmithKline Consumer Healthcare Limited today declared its financial results for the second quarter ended September 30, 2017. The comparable* revenue for the company recorded a growth of 4.8%. Levy of excise duty, octroi, non-cenvatable service tax etc., which were treated as part of the cost earlier is now included under GST and is netted off from turnover resulting in reduction in reported revenue. Owing to this GST accounting, the quarter recorded sales at Rs.1115 crores.
PBT for the quarter is at Rs. 298 crores, which is a growth of 3.6%.
Commenting on the results, Manoj Kumar, Managing Director, GlaxoSmithKline Consumer Healthcare Limited said, “Our revenue in domestic market has grown by 6.4% driven by market penetration, increased access to products and stepped up investments on advertising and promotion. Horlicks and Boost continue to have strong consumer connect, backed by seamless on-ground execution. Our GST transition has been overall smooth & swift without any major business disruption.”
“We are confident that with the stabilization of GST implementation the external environment will be more conducive to growth. This coupled with strong brands based on high science, our continuous focus on innovation and sharp customer insights, will help us to remain ahead in the category.” he added.
•Horlicks sachet continues to drive penetration
•Boost remains a strong performer
•Advertising and promotion investment stepped up
Health Food Drinks – Market share
•Our health food drink portfolio continues to be the market leader with 55.6% (Value share) and 63.9% (Volume share) – (MAT September 2017)
About GlaxoSmithKline Consumer Healthcare Ltd
GSK Consumer Healthcare Ltd is the category leader in Indian health food drinks industry. Our flagship product Horlicks leads the market, while Boost is among the top three health food drink brands that India prefers. Our manufacturing plants are located in Nabha, Rajahmundry and Sonepat. In India we have an engaged workforce of over 3800 employees. GSK also markets and distributes a range of everyday health products such as Eno, Crocin, Iodex and Sensodyne. Our marketing and distribution network comprises over 700 distributors and a direct coverage of over 8 lakh retail outlets.
GSK Consumer Healthcare Ltd is an associate of GlaxoSmithKline plc.of U.K, one of world’s largest consumer healthcare companies. We have a heritage that goes back over 160 years. Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products. Our goal is to build a global, growing business - we call a Fast Moving Consumer Healthcare (FMCH) company - dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.
GSK Consumer Healthcare globally owns some of the world’s best loved healthcare brands, successful in over 100 countries. These include Sensodyne, Theraflu, Paradontax, Panadol, Polident, Otrivin, Horlicks and Physiogel.
*Comparable: Reflecting the accounting impact of GST (Excise and other tax costs under earlier regime, now subsumed under GST and netted from Turnover in base)
Rikhil Seth: email@example.com / +91 9811818270
M Sindhu: firstname.lastname@example.org /+91 9899428304
GlaxoSmithKline Consumer Healthcare
Deepa Dey: email@example.com
Kinshuk Gupta: firstname.lastname@example.org